Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use (CHMP) is responsible for the scientific evaluation of licensing dossiers with regard to quality, efficacy, and safety (including environmental risk assessments) of new medicinal products in the course of centralised licensing procedures. The CHMP's scientific assessment report is the basis for the European Commission's decision on granting or refusing a central marketing authorisation of a medicinal product for human use.
The Committee for Medicinal Products for Human Use consists of scientific experts from all Member States of the EEA; for further information on the Committee for Medicinal Products for Human Use (CHMP) please visit the European Medicines Agency's website.
For an overview of all centrally licensed medicinal products please refer to the European Commission's Community Register of medicinal products for human use.